Bicycle raises £40mCambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties. more ➔
wikicommons EC and EMA provide Brexit guidanceUK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch … more ➔
Addex further improves liquidityFollowing a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and … more ➔
AMO Pharma receives FDA Fast Track Status London-based orphan drug developer AMO Pharma’s drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy. more ➔
Biocorp partners with VirbacFrench drug delivery specialist Biocorp S.A. (Issoire) has signed an industrialisation contract with Virbac, one of the top-ten vet-med makers. more ➔
Janssen speeds up guselkumab approval proc...Janssen speeds up US approval of psoriasis antibody guselkumab and targets further indications. more ➔
Abzena’s partner True North Therapeu...British Abzena plc has announced that True North Therapeutics (TNT) will be taken over by Bioverativ Inc. Bioverativ will further develop TNT’s complement factor C1-blocking antibody TNT009, developed … more ➔
RA: Sanofi/Regeneron IL-6R blocker FDA-app...Following the EMA’s recommendation for EU approval of sarilumab as second-line treatment for rheumatoid arthritis, French drug giant Sanofi and partner Regeneron have also been given the green light … more ➔
Safety event delays US market approval of...Top-Line Phase 3 data of Amgen’s/UCB’s osteoporosis antibody romosozumab in postmenopausal women suggest efficacy but uncover a new safety signal. more ➔
Vesalius Biocapital fund raises €65mLuxembourg-based venture capital specialist Vesalius Biocapital has closed the first round of Biocapital III fund that aims to invest into later-stage European life sciences companies. more ➔
wikicommons
